Direkt zum Inhalt
Merck

Preventive effect of Imperatorin on acute lung injury induced by lipopolysaccharide in mice.

International immunopharmacology (2012-08-11)
Jingjing Sun, Gefu Chi, Lanan Wassy Soromou, Na Chen, Mingfeng Guan, Qianchao Wu, Dacheng Wang, Hongyu Li
ZUSAMMENFASSUNG

Imperatorin, a linear furanocoumarin, has many pharmacological effects such as antibacterial, anti-inflammatory and antiviral effects. The purpose of this study was to investigate the effect of Imperatorin on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. BALB/c mice were pretreated with Imperatorin 1h before LPS challenge. We found that the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in the bronchoalveolar lavage fluid (BALF) were decreased significantly, and the level of interleukin-10 (IL-10) was up-regulated 8h after Imperatorin treatment. Pretreatment with Imperatorin (15 or 30 mg/kg) decreased lung wet-to-dry weight (W/D) ratio, the number of inflammatory cells and myeloperoxidase (MPO) activities. Additionally, Imperatorin attenuated lung histopathological changes and significantly inhibited the phosphorylation of IκB, JNK, ERK and p38/MAPK. These findings demonstrate that Imperatorin protects against LPS-induced ALI in mice.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Imperatorin, ≥98% (HPLC), powder